Tigecycline therapy in pediatric patients with multidrug resistant bacteremia
| Autor: | Hasan Tezer, Saliha Kanik-Yuksek, Belgin Gülhan, Aslinur Ozkaya-Parlakay, Sevim Ünal, Doğuş Güney, Emrah Şenel, Gökhan Demirtaş, Deniz Gönülal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Drug medicine.medical_specialty Combination therapy media_common.quotation_subject 030106 microbiology Bacteremia Tigecycline 03 medical and health sciences 0302 clinical medicine Internal medicine Drug Resistance Multiple Bacterial Medicine Humans 030212 general & internal medicine Child media_common Retrospective Studies business.industry medicine.disease Anti-Bacterial Agents Multiple drug resistance Multidrug resistant bacteria business medicine.drug |
| Zdroj: | Enfermedades infecciosas y microbiologia clinica (English ed.). 38:471-473 |
| ISSN: | 2529-993X |
| DOI: | 10.1016/j.eimce.2019.12.014 |
| Popis: | Introduction Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients. Methods In this study the effectiveness and safety of tigecycline in children was assessed retrospectively. Results A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2–32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse. Conclusion Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect